Table 2.

Immunogenicity response.

	GMC (95% CI)	n/N*	Proportion of subjects seroresponding (IgA $\ge$ 20 U/mL) (95% CI)
Group 1 RV1-RV1-Placebo	109.7 (89.7, 134.3)	109/141	0.77 (0.7005, 0.8439)
Group 3 RV1-RV5-RV5	576.97 (477.7, 696.8)	141/146	0.97a (0.9423, 0.9976)
Group 7 RV1-RV5-RV1	369.52 (298.7,457.2)	141/146	0.97a (0.9423, 0.9976)
Group 2 RV5-RV5-RV5	766.0 (627.5, 935.1)	147/147	1.00
Group 4 RV5-RV1-RV1	516.0 (412.9, 644.8)	137/144	0.95 (0.9144, 0.9855)
Group 5 RV5-RV5-RV1	692.8 (574.4, 835.7)	143/147	0.97 (0.9144, 0.9855)
Group 6 RV5-RV1-RV5	582.6 (462.3, 734.2)	139/143	0.97 (0.9424, 0.9975)
Total	473.7 (434.8, 515.9)	958/1014	0.94 (0.9258, 0.9546)

*n, number of seroresponding subjects; N, total number of participants per group; GMC, Geometric mean concentrations of antibody titers; 95% CI, 95% confidence interval.

^aDifference of proportion test p-value < 0.001 vs. Group 1 (RV1-RV1-placebo).